New drug cocktail targets tough ovarian cancer in japanese women

NCT ID NCT06682572

Ongoing Disease control Sponsor: Verastem, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests a combination of two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has returned after platinum-based chemotherapy. The goal is to see if the combo can shrink tumors and how safe it is. The trial is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: avutometinib and defactinib (combination pill)
What this could lead to: If successful, this could provide a new treatment option for Japanese patients with recurrent low-grade serous ovarian cancer, potentially shrinking tumors or slowing disease progression.
What could go wrong: This is a small, early-phase trial with only 16 participants, so results may not apply to all patients. The combination may cause side effects and may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOW GRADE SEROUS OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

borderline ovarian serous tumor ovarian cancer ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOW GRADE SEROUS OVARIAN CANCER OVARIAN CANCER

Contacts and locations

Locations

Aichi Cancer Center Hospital

Nagoya, Aichi-ken, 464-8681, Japan
Jikei University Hospital

Minato, Tokyo, 105-0003, Japan
Kurume University Hospital

Kurume, Fukuoka, 830-0011, Japan
Mie University Hospital

Tsu, Mie-ken, 514-8507, Japan
Tohoku University Hospital

Sendai, Miyagi, 980-8574, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.